PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells

Inclusion Criteria: * Age between 18 and 70 years * Clinical diagnosis and imaging (Rx and NMR) of idiopathic osteonecrosis of the femoral head * Stadiums \<IIIC ARCO ranking Exclusion Criteria: * Those on investigator judgment not in a good position to tolerate the procedure. * Clinical criteria and anesthetics that contraindicate surgery (eg ASA IV-V) * Serious illness uncontrolled * Pregnant women * Patients with HIV infection + * Acute infection (in the previous 15 days) or chronic (other than HIV) * Previous treatments of osteonecrosis * Active or previous neoplastic disease (last 5 years) except for patients undergoing allogeneic haematopoietic progenitors who are in complete remission after 2 years after transplantation. * Lack of informed consent or revocation thereof.